Intravitreal bevacizumab treatment of radiation maculopathy due to brachytherapy in choroidal melanoma.
Ziemssen
Focke
F
Voelker
Michael
M
Altpeter
Elke
E
Bartz-Schmidt
Karl U
KU
Gelisken
Faik
F
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001918:Brachytherapy / Q000009:adverse effects*; D002830:Choroid Neoplasms / Q000532:radiotherapy*; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008297:Male; D008545:Melanoma / Q000532:radiotherapy*; D008875:Middle Aged; D011832:Radiation Injuries / Q000188:drug therapy* / Q000209:etiology; D012160:Retina / Q000528:radiation effects*; D012429:Ruthenium Radioisotopes / Q000009:adverse effects; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D012429:Ruthenium Radioisotopes; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab